TABLE 1.
Baseline characteristics in the study cohort.
| Characteristics | TACE-refractory group (n = 93) | TACE-non-refractory group (n = 20) | p Value |
|---|---|---|---|
| Age, yr, mean (range) | 61.33 (33–89) | 66.30 (36–90) | 0.129 |
| Sex (male/female) | 83/10 (89%) | 18/2 (90%) | 1.000 |
| Hepatitis B (yes/no) | 67/26 (72%) | 17/3 (85%) | 0.273 |
| PS (0/1) | 65/28 (70%) | 16/4 (80%) | 0.425 |
| TBIL (μmol/L), mean ± SD | 18.19 ± 12.97 | 16.93 ± 8.64 | 0.680 |
| ALB (g/L), mean ± SD | 36.28 ± 5.31 | 37.74 ± 5.02 | 0.263 |
| AST (IU/L), mean ± SD | 51.05 ± 62.10 | 48.25 ± 34.43 | 0.846 |
| ALT (IU/L), mean ± SD | 40.01 ± 36.46 | 45.10 ± 25.25 | 0.554 |
| WBC (109/L), mean ± SD | 5.75 ± 2.23 | 6.09 ± 2.87 | 0.547 |
| Hb (g/L), mean ± SD | 134.56 ± 18.77 | 135.05 ± 18.62 | 0.916 |
| BCLC stage (A/B) | 20/73 (22%) | 9/11 (45%) | 0.029 |
| HKLC stage (I/II/III) | 21/32/40 | 7/9/4 | 0.133 |
| TN, mean ± SD | 3.34 ± 1.61 | 2.05 ± 1.23 | 0.001 |
| TD, cm, mean ± SD | 7.26 ± 4.31 | 7.02 ± 3.99 | 0.819 |
| BI (yes/no) | 47/46 (51%) | 1/19 (5%) | <0.001 |
PS: physical status; TBIL: total bilirubin; ALB: albumin; AST: aspartate transaminase; ALT: alanine aminotransferase; WBC: white blood cell count; TN: tumor number; TD: tumor diameter; BI: bilobular invasion; SD: standard deviation.